Conference Day Two
Wednesday, June 12

7:30 am Registration & Coffee Room Networking

8:20 am Opening Remarks

8:30 am Panel Discussion: Which Cell Type has the Most Promise as a Future Leader of Allogeneic Cell Therapy?

  • Richard Wang Chief Executive Officer, Neukio Biotherapeutics
  • Xi shi Director of Oncology Cell Therapy Innovation & Head of Technology Incubation Engine, Takeda New!
  • Tirtha Chakraborty Chief Scientific Officer, Vor Biopharma


  • Engaging in a dynamic panel discussion to explore the potential of various cell types as future leaders in allogeneic cell therapy
  • Evaluating the unique attributes and therapeutic advantages offered by different cell types under consideration
  • Facilitating an insightful conversation on the challenges, opportunities, and key criteria influencing the selection of the most promising cell type for the future of allogeneic cell therapy

9:00 am Poseida Therapeutics: Clinical Data Presentation


  • Presenting refreshed data from P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma
  • Utilizing next-gen allogeneic CAR-Ts with safer, non-viral delivery to unlock new cancer-fighting potential
  • Leveraging partnerships to conquer hematological malignancies with novel allogeneic therapies

9:30 am Unleashing the Potential of CAR-T in Earlier Lines of Cancer Treatment & Beyond

  • Zachary Roberts Executive Vice President, Research & Development & Chief Medical Officer, Allogene Therapeutics


  • The inherent limitations of autologous CAR-T therapies do not allow them to be delivered on demand and at scale where patients are most treated, a problem that will only grow as CAR-T expands into earlier lines of treatment and diseases beyond oncology
  • Allogene’s core programs capitalize on the specific attributes of an allogeneic CAR-T for development and trial design to unleash the potential of the modality
  • The potential for an allogeneic CAR-T to leapfrog other CAR-Ts and embed in the first line setting and transform autoimmune disease management with reduced or chemotherapy-free lymphodepletion

10:00 am Morning Refreshment Break & Networking Break


As the allogeneic community is reunited, this session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don’t forget to enjoy some refreshments before we split off into the 3 different tracks: Pre-Clinical, Clinical and Manufacturing & Process Development


Enhancing the Targeting & Infiltration of Solid Tumors

11:30 am Identifying Novel Cancer Biomarkers that Indicate Responsiveness to Allogeneic Cell Therapies


  • Discussing the implications of biomarker discovery for patient stratification and treatment outcomes
  • Sharing case studies and advancements in identifying predictive biomarkers for allogeneic cell therapies
  • Utilizing the selective and anti-tumor properties of NK cells to achieve tumor control and immune recruitment in solid tumors

12:00 pm Investigating Strategies for Trafficking & Infiltration of Allogeneic Cells into Solid Tumors

  • Rosa Ng Associate Director, Cell Therapy Innovation, Takeda New!


  • Assessing the impact of cell migration on therapeutic efficacy and tumor penetration
  • Highlighting pre-clinical and clinical insights to optimize the delivery of allogeneic cells for improved anti-tumor responses


Innovating in Allogeneic Clinical Trials to Bring Benefit to Patients Faster

11:30 am Optimizing Clinical Trials Using Global Patient Populations to Make Off-the-Shelf Therapies Truly Accessible


  • Exploring global trial strategies to broaden patient participation and increase accessibility to allogeneic therapies
  • Discussing regulatory considerations, logistical challenges, and success stories from global trial initiatives

12:00 pm Protecting Patients by Removing Need for Lymphodepletion to Better Preserve Immune Function

  • Paul Song Chief Scientific Officer, NKGen Biotech New!


  • Trialing a novel allogeneic blood-derived NK therapy to treat patients with refractory solid tumors
  • Removing the need for lymphodepletion to better preserve patient immune function hopefully allowing for better reliance and recovery •
  • Unveiling an unexpected finding from the study that may give SNK02 applications to disease areas outside of oncology


Advancements in Delivery & Storage of Allogeneic Cell Therapy Products

11:30 am Making the Ideal CDMO Match for Allogeneic Cell Therapy

  • Lan Le Senior Director, Aurion Biotech


  • Company, know thyself. Start with a clear understanding of program needs and priorities
  • CDMO, know thy prospective client. Must-do’s and pitfalls to avoid in the selection process
  • Structuring for success: key considerations to optimize the external manufacturing partnership

12:00 pm Panel: Are CDMO ready for phase appropriate manufacturing to move customer’s cell therapy programs ahead?

  • Amish Patel Senior Vice President - Technical Operations, Calidi Biotherapeutics Inc.
  • Lan Le Senior Director, Aurion Biotech


  • Is cryopreservation a must in cell therapy products?
  • Understanding the current status of cryopreservation in allogeneic cell products
  • Assessing the future directions for cyropreservation to improve efficacy and storage

12:30 pm Lunch Refreshment

Mitigating Safety Risks & Challenges for Allogeneic Products

2:00 pm Leveraging the Unique Characteristics of NK Cells to Overcome Current Safety Concerns

  • Wei Li Chief Scientific Officer, Cytovia Therapeutics New!


  • Understanding the benefits of NK cells such as facilitating engraftment and reducing risk of GVHD
  • Considering the benefits of NK cells when paired with the manufacturing efficiencies offered by iPSCs
  • Highlighting the mechanisms of action employed by NK cells to effectively suppress T-cell alloreactivity

2:30 pm Defining Tolerable Safety Profiles for Novel Applications of Allogeneic Therapies


  • Tailoring safety measures to address unique disease features in therapeutic interventions
  • Examining risk-benefit assessments and criteria for determining safety thresholds
  • How does the Tmod™ dual receptor system allow targeting of hard-to-target tumor antigens?

3:00 pm Leveraging Gamma Delta Cells to Enhance Accessibility of Allogeneic Therapies

  • Jeff Liter Chief Executive Officer, Luminary Therapeutics


  • Exploring the Allogeneic Gamma 2.0+ Platform as a rapidly expanding solution to make off-the-shelf therapies more cost effective
  • Enhancing T-cell expansion to minimize dosing delays, effectively catering to patients with hard-to-treat diseases
  • Strategizing ways to enhance cost-effectiveness in the production of allogeneic cell therapies for broader patient accessibility

Preparing Allogeneic Cells Against Immunosurveillance

2:00 pm Minimizing Alloreactivity through Innovative Stealth Approaches


  • Exploring strategies for evading detection and recognition by the immune system
  • Potency vs stealth: evaluating prioritization of therapy characteristics dependent on disease type and severity

2:30 pm Highlighting Cell Armoring Strategies to Protect Allogeneic Products During Delivery

  • Jeffrey Miller Professor of Medicine, Division of Hematology, Oncology and Transplantation Deputy Director, Masonic Cancer Center, Masonic Cancer Center New!


  • Utilizing novel platforms to reduce immunogenicity of allogeneic therapies across cell types
  • Assessing shielding technologies to protect allogeneic cells from immune surveillance
  • How can we combat T-Cell exhaustion to create a sustain and effective therapeutic?

3:00 pm Overcoming Immunogenicity Using Novel Gene Edits


  • Discussing the latest advancements in gene editing technologies for reducing immune responses
  • Sharing case studies and research outcomes demonstrating the effectiveness of novel gene edits in mitigating immunogenicity

Implementing Effective Allogeneic Cell Therapy QC & Characterization

2:00 pm Defining PK & PD of Allogeneic Cell Therapies to Drive Clinical Precision


  • Discussing the importance of precisely defining the identity of the allogeneic cell therapy in clinical settings
  • Exploring regulatory expectations, quality control measures, and standardization approaches for product identity

2:30 pm Designing Screening Protocols to Build a Scalable Diverse Donor Pool for Off-the-Shelf Product Manufacturers

  • Mamta Kalra Senior Director - Process, Analytical Development Chemistry Manufacturing and Controls, Immatics GmbH


  • Exploring strategies for designing screening protocols to build a scalable and diverse donor pool for allogeneic therapy production
  • Discussing considerations for donor selection, screening criteria, and ethical considerations in donor recruitment

3:00 pm Assessment of Immunogenicity associated with Allogeneic CAR-T Cell Therapy

  • Lalit Kumar Director - Clinical Bioanalytics & Translational Science, Beam Therapeutics New!


  • Examining the relevance of Human Leukocyte antigen (HLA) types
  • Determining the anti-drug antibody (ADA) response: strategies and implications
  • Evaluating the role of cellular immune response and its measurement strategies

3:30 pm Afternoon Break & Refreshments

Improving Durability & Persistence of Allogeneic Cell Therapies

4:30 pm Leveraging a Novel Non-Gene Edited Platform to Enhance the Persistence & Efficacy of Allogeneic Cell Therapies


  • Showcasing the development and proof of concept of a novel miRNA-based platform that allows for the multiplexed modulation of genes simultaneously
  • Exploring multiplexed miRNA-based technology for the development of an allogeneic CAR-T that is resistant to both NK and T-cell recognition and allows for improved longevity of therapies
  • Enhancing allogeneic CAR-T therapies beyond the current challenges and consider the implications of these findings for future therapies

5:00 pm Evaluating On-Off Switch Technologies & Redosing Models to Create an Inducible Off-the-Shelf Cell Therapy


  • Considering the potential of on-off switch technologies as inducible therapeutic approaches for allogeneic cell therapies
  • Understanding the option of redosing with allogeneic therapies to mitigate challenges with toxicity for patients with recurring disease

5:30 pm Closing Remarks & End of Conference